Name: Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Long-term morbidity
Published: 2026-09-28T12:24:10-04:00

Product information and disease description Place of product in therapy Disease description

Long-term morbidity

4 evidence topics · 3 sources

Falls and fall-related injury

“They are twice as common among older people with AMD” (opens the source at this quote in a new tab)

“35% of the participants reporting that they had incurred injuries during a fall” (opens the source at this quote in a new tab)

Concern about falling

“high CF (FES-I ≥ 23) was identified in just under half of the participants (48%) at baseline, and the proportion increased significantly to 65% at follow-up” (opens the source at this quote in a new tab)

Anxiety and depression

“Clinically significant severity of depression symptoms was found in 4.2% of patients, mild manifestations of depression were found in 8.3%” (opens the source at this quote in a new tab)
“79.2% demonstrated moderate reactive anxiety; 12.5% of the subjects had a low level of reactive anxiety. 81.7 % of the respondents were subject to moderate and high personal anxiety.” (opens the source at this quote in a new tab)

Progressive fibrotic scarring

“large disciform scars are rarely encountered in the clinic. However long-term studies show that smaller and less severe fibrotic scars are not uncommon and develop over time despite optimal treatment.” (opens the source at this quote in a new tab)